BioSpace News Archive

Avadel Pharmaceuticals plc announced that it has achieved its patient enrollment target of 205 patients in the REST-ON Phase 3 clinical trial for its once-nightly sodium oxybate, FT218.

Tetra Bio-Pharma Inc., announced that the U.S. Food and Drug Administration has authorized the advancement of Plenitude, the company’s clinical trial for its investigational therapeutic QIXLEEF™, for the treatment of uncontrolled pain in advanced cancer patients.

PDS Biotechnology Corporation announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Company’s novel T-cell activating immunotherapy platform, Versamune®, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.

Marinomed Biotech AG has presented detailed data from its pivotal Phase III clinical trial for the therapeutic comparability of an aqueous solution of budesonide, a synthetic steroid for the treatment of hay fever.

Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead

BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology, announced that it will host an investor breakfast meeting on Thursday, December 5, 2019 at the Convene Conference Center near Grand Central Terminal in New York, N.Y.

Filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Types 1, 2 or 3 SMA

Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced the appointment of Jonathan Biller to the newly created role of chief legal officer effective December 3, 2019.

Plus Therapeutics, Inc. announced that it will be participating at the upcoming 12th annual LD Micro Main Event.